Literature DB >> 27630935

Cisplatin Concentrations in Long and Short Duration Infusion: Implications for the Optimal Time of Radiation Delivery.

Pradeep Rajkumar1, Binu Susan Mathew2, Saikat Das3, Rajesh Isaiah3, Subashini John4, Ratna Prabha5, Denise Helen Fleming6.   

Abstract

INTRODUCTION: Cisplatin has radiosensitizing properties and the best sensitization to radiotherapy occurs with a higher plasma concentration of cisplatin. To our knowledge the optimal time sequence between chemotherapy and administration of radiation therapy, to obtain maximum effect from concurrent chemoradiation is unclear. AIM: The aim of this study was to measure the two cisplatin infusion regimens in order to determine the total and free cisplatin post infusion concentration changes over time. These changes may have clinical implications on the optimum time of administration of post infusion radiation therapy.
MATERIALS AND METHODS: Two cohorts of patients were recruited and both, total and free plasma concentration of cisplatin following long and short durations of intravenous infusion was determined. Blood samples were collected at 0.5, 1, 1.5, 2, 3 and 5 hours from the start of the infusion in the 1hour infusion group and at 2, 3, 3.5, 4, 6 and 24 hours from the start of the infusion, in the 3 hour infusion group. Total and free cisplatin concentrations were measured using a validated HPLC-UV method.
RESULTS: The highest concentration of total and free cisplatin was achieved at the end of the infusion in both regimens. Total cisplatin concentration declined 30 minutes after the end of infusion in both the groups. After 1hour of discontinuing cisplatin, the free cisplatin concentration also declined significantly.
CONCLUSION: We conclude that radiation should be administered within 30 minutes of completion of the infusion irrespective of the duration of infusion.

Entities:  

Keywords:  Chemotherapy; Radiation therapy; Radiosensitizing

Year:  2016        PMID: 27630935      PMCID: PMC5020194          DOI: 10.7860/JCDR/2016/18181.8126

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  17 in total

1.  Effectiveness in inhibition of recovery of cell survival by cisplatin and carboplatin: influence of treatment sequence.

Authors:  J H Schwachöfer; R P Crooijmans; J Hoogenhout; H B Kal; A G Theeuwes
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-06       Impact factor: 7.038

2.  Chemical reactivity of cisplatin bound to human plasma proteins.

Authors:  L Hegedüs; W J van der Vijgh; I Klein; S Kerpel-Fronius; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Scheduling cisplatin and radiotherapy in the treatment of squamous cell carcinomas of the head and neck: a modelling approach.

Authors:  L Marcu; E Bezak; I Olver
Journal:  Phys Med Biol       Date:  2006-07-12       Impact factor: 3.609

Review 4.  Cisplatin and radiation: interaction probabilities and therapeutic possibilities.

Authors:  A C Begg
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-11       Impact factor: 7.038

5.  A performance status scale for head and neck cancer patients.

Authors:  M A List; C Ritter-Sterr; S B Lansky
Journal:  Cancer       Date:  1990-08-01       Impact factor: 6.860

6.  Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration.

Authors:  K Ikeda; M Terashima; H Kawamura; I Takiyama; K Koeda; A Takagane; N Sato; K Ishida; T Iwaya; C Maesawa; H Yoshinari; K Saito
Journal:  Jpn J Clin Oncol       Date:  1998-03       Impact factor: 3.019

7.  High-performance liquid chromatographic determination of cis-dichlorodiammineplatinum(II) in plasma ultrafiltrate.

Authors:  V Augey; M Cociglio; M Galtier; R Yearoo; V Pinsani; F Bressolle
Journal:  J Pharm Biomed Anal       Date:  1995-08       Impact factor: 3.935

8.  Fatal overdosage with cisplatin.

Authors:  C Charlier; P Kintz; N Dubois; G Plomteux
Journal:  J Anal Toxicol       Date:  2004-03       Impact factor: 3.367

9.  Population pharmacokinetics of total and unbound plasma cisplatin in adult patients.

Authors:  Sail Urien; François Lokiec
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

10.  Validation of a liquid chromatography post-column derivatization assay for the determination of cisplatin in plasma.

Authors:  H H Farrish; P H Hsyu; J F Pritchard; K R Brouwer; J Jarrett
Journal:  J Pharm Biomed Anal       Date:  1994-02       Impact factor: 3.935

View more
  16 in total

1.  Mass Spectrometry Based Proteomics Study of Cisplatin-Induced DNA-Protein Cross-Linking in Human Fibrosarcoma (HT1080) Cells.

Authors:  Xun Ming; Arnold Groehler; Erin D Michaelson-Richie; Peter W Villalta; Colin Campbell; Natalia Y Tretyakova
Journal:  Chem Res Toxicol       Date:  2017-03-29       Impact factor: 3.739

2.  Quantitative prediction of human pharmacokinetic responses to drugs via fluidically coupled vascularized organ chips.

Authors:  Anna Herland; Ben M Maoz; Debarun Das; Mahadevabharath R Somayaji; Rachelle Prantil-Baun; Richard Novak; Michael Cronce; Tessa Huffstater; Sauveur S F Jeanty; Miles Ingram; Angeliki Chalkiadaki; David Benson Chou; Susan Marquez; Aaron Delahanty; Sasan Jalili-Firoozinezhad; Yuka Milton; Alexandra Sontheimer-Phelps; Ben Swenor; Oren Levy; Kevin K Parker; Andrzej Przekwas; Donald E Ingber
Journal:  Nat Biomed Eng       Date:  2020-01-27       Impact factor: 25.671

3.  The effect of a chemotherapy drug cocktail on myotube morphology, myofibrillar protein abundance, and substrate availability.

Authors:  Stephen Mora; Olasunkanmi A J Adegoke
Journal:  Physiol Rep       Date:  2021-07

4.  Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ.

Authors:  Liang Song; Ewan M McNeil; Ann-Marie Ritchie; Katy R Astell; Charlie Gourley; David W Melton
Journal:  BMC Cancer       Date:  2017-12-18       Impact factor: 4.430

5.  The identification of dual protective agents against cisplatin-induced oto- and nephrotoxicity using the zebrafish model.

Authors:  Jaime N Wertman; Nicole Melong; Matthew R Stoyek; Olivia Piccolo; Stewart Langley; Benno Orr; Shelby L Steele; Babak Razaghi; Jason N Berman
Journal:  Elife       Date:  2020-07-28       Impact factor: 8.140

6.  Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors.

Authors:  Ratnakar Singh; Zeeshan Fazal; Andrea K Corbet; Emmanuel Bikorimana; Jennifer C Rodriguez; Ema M Khan; Khadeeja Shahid; Sarah J Freemantle; Michael J Spinella
Journal:  Cancers (Basel)       Date:  2019-06-08       Impact factor: 6.639

Review 7.  Xenobiotic metabolism and transport in Caenorhabditis elegans.

Authors:  Jessica H Hartman; Samuel J Widmayer; Christina M Bergemann; Dillon E King; Katherine S Morton; Riccardo F Romersi; Laura E Jameson; Maxwell C K Leung; Erik C Andersen; Stefan Taubert; Joel N Meyer
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2021-02-22       Impact factor: 8.071

8.  Surgery combined with radio-chemotherapy for esophageal mucoepidermoid carcinoma: A case report.

Authors:  Chunhui Zheng; Xiaomei Chen; Fangbiao Zhang; Liping Yan; Xiangyan Zhang
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

9.  Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells.

Authors:  Andrew Sulaiman; Sarah McGarry; Jason Chambers; Emil Al-Kadi; Alexandra Phan; Li Li; Karan Mediratta; Jim Dimitroulakos; Christina Addison; Xuguang Li; Lisheng Wang
Journal:  Int J Mol Sci       Date:  2020-08-12       Impact factor: 5.923

10.  Metabolic interaction between amino acid deprivation and cisplatin synergistically reduces phosphoribosyl-pyrophosphate and augments cisplatin cytotoxicity.

Authors:  Nisreen Wahwah; Debanjan Dhar; Hui Chen; Shunhui Zhuang; Adriano Chan; Darren E Casteel; Hema Kalyanaraman; Renate B Pilz; Gerry R Boss
Journal:  Sci Rep       Date:  2020-11-16       Impact factor: 4.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.